US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Cigna (NYSE:CI) on Tuesday filed an antitrust lawsuit accusing Bristol Myers Squibb (NYSE:BMY) of breaching U.S. competition ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Pomalyst accounted for sales of more than $3 billion in each of the last five years, including $3.55 billion in 2024, accounting for 7% of Bristol's overall revenue of $48 billion. Related ...

Bristol Myers (BMY) Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an illegal monopoly on its ...

Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an illegal monopoly on its blockbuster ...

It includes Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic, as well as Xtandi, Ibrance, Calquence and Pomalyst, drugs that treat prostate, breast, blood and bone marrow cancers.

Patients with relapsed/refractory multiple myeloma tended to live longer without their disease worsening (progression-free survival; PFS) when treated with Blenrep (belantamab mafodotin-blmf) plus ...

Bristol Myers Squibb acquired Pomalyst when it purchased Celgene for $74 billion (₹6.15 lakh crore) in 2019. In 2022, Pomalyst generated nearly $3.5 billion (₹30,000 crore) in revenue, marking ...